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Neurexins and neuroligins provide trans-synap-
tic connectivity by the Ca2+-dependent interac-
tion of their alternatively spliced extracellular
domains. Neuroligins specify synapses in an
activity-dependent manner, presumably by bind-
ing to neurexins. Here, we present the crystal
structures of neuroligin-1 in isolation and in
complex with neurexin-1b. Neuroligin-1 forms
a constitutive dimer, and two neurexin-1bmono-
mers bind to two identical surfaces on the op-
posite faces of the neuroligin-1 dimer to form
a heterotetramer. The neuroligin-1/neurexin-1b
complex exhibits a nanomolar affinity and in-
cludes a large binding interface that contains
bound Ca2+. Alternatively spliced sites in neu-
rexin-1b and in neuroligin-1 are positioned
nearby the binding interface, explaining how
they regulate the interaction. Structure-based
mutations of neuroligin-1 at the interface dis-
rupt binding to neurexin-1b, but not the folding
of neuroligin-1 and confirm the validity of the
binding interface of the neuroligin-1/neurexin-
1b complex. Our results provide molecular in-
sights for understanding the role of cell-adhe-
sion proteins in synapse function.
INTRODUCTION
Synapses are asymmetric cell-cell junctions that mediate
communication between neurons. The formation of an ini-
tial synaptic contact is followed either by thematuration or
by the elimination of the synapse, depending on the syn-
aptic activity it experiences. Synapse specification and992 Neuron 56, 992–1003, December 20, 2007 ª2007 Elseviervalidation is critical for normal functioning of the brain,
and impairments in synapse development are thought to
be a major cause of brain disorders such as autism and
mental retardation (Garber, 2007).
Neuroligins (NLs) are transmembrane proteins on the
postsynaptic cell surface (Ichtchenko et al., 1995; Ichtch-
enko et al., 1996). They were discovered as ligands (or re-
ceptors) for neurexins (Nrxs), which are synaptic cell
adhesion proteins on the presynaptic cell surface
(Ushkaryov et al., 1992; Missler et al., 2003). The extracel-
lular domains of NLs and neurexins interact in a Ca2+-de-
pendent manner (Nguyen and Sudhof, 1997). Neuroligin-
1 (NL1) expressed in nonneuronal HEK293 cells induces
presynaptic differentiation in cocultured neurons at the
sites of cell-cell contact (Scheiffele et al., 2000; Fu
et al., 2003; Boucard et al., 2005; Chubykin et al., 2005;
Chih et al., 2006). Similarly, neurexins expressed in non-
neuronal cells induce postsynaptic differentiation in cul-
tured neurons at contact sites (Graf et al., 2004; Nam
and Chen, 2005). These observations led to the hypothe-
sis that NL and Nrx act as transneuronal signals for the re-
cruitment of synaptic components and might be involved
in initial synapse formation in vivo (Dean and Dresbach,
2006; Craig and Kang, 2007). However, results from
knockout (KO) mice revealed that neither NLs nor Nrxs
are required for the initial synapse formation in vivo as
no defects in the synapse numbers were observed in
the KO mice (Missler et al., 2003; Varoqueaux et al.,
2006). On the other hand, NL and Nrx were found to be
critical for synapse function and mouse survival. Further
studies showed that NLs do not establish, but specify
and validate, synapses via an activity-dependent mecha-
nism, probably by determining whether a synapse will be
excitatory or inhibitory, stable or transient, facilitating or
depressing (Chubykin et al., 2007). Indeed, physiological
experiments with NL1 and neuroligin-2 (NL2) KO mice in
combination with overexpression experiments showed
that NL1 and NL2 selectively act on excitatory andInc.
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Interaction between Neuroligin and Neurexininhibitory synapses, respectively, to validate synapses
(Chubykin et al., 2007).
Mutations in neuroligins and neurexins were described
as rare causes of familial autism spectrum disorders
(Jamain et al., 2003; Laumonnier et al., 2004; Yan et al.,
2005; Szatmari et al., 2007). Introduction of an autism mu-
tation (R451C on NL3) caused an increase in inhibitory
synaptic activity and produced autism-like behavior in
knock-in mice (Tabuchi et al., 2007). The identification of
autistic patients with either NL or Nrx mutations sug-
gested that the NL/Nrx interaction and its downstream
signaling pathways might be disrupted in autism disor-
ders. Consistent with this notion, mutations in Shank3,
a postsynaptic scaffolding molecule that indirectly inter-
acts with NLs, were also found in autism spectrum disor-
ders (Durand et al., 2007).
Five NL genes exist in humans, and four in rodents
(Ichtchenko et al., 1996; Philibert et al., 2000; Bolliger
et al., 2001; Jamain et al., 2003). NLs are type-I membrane
proteins with a molecular mass of approximately 95 kDa,
predicted to have a single transmembrane helix. Their ex-
tracellular region consists of a single esterase domain that
is enzymatically inactive. Although the NL-esterase do-
main has 34% sequence identity to acetylcholinesterase
(AChE) (Sussman et al., 1991), it has a unique glycosyla-
tion pattern, an additional disulfide bond, and alternatively
spliced sites (Comoletti et al., 2003; Hoffman et al., 2004).
NLs are alternatively spliced at two positions (A and B)
(Ichtchenko et al., 1995; Ichtchenko et al., 1996), with
splice site A containing two distinct inserts in most NLs,
whereas splice site B appears to be only used in NL1 (Co-
moletti et al., 2007).
Three Nrx genes are present in humans and rodents,
with each gene producing longer a- and shorter b-neurex-
ins (Ushkaryov et al., 1992). The extracellular sequences of
b-Nrxs are largely composed of a single laminin/neurexin/
sex hormone binding globulin (LNS) domain, whereas the
extracellular sequences of a-Nrxs contains six LNS do-
mains and additionally include three epidermal growth
factor (EGF) domains (Missler et al., 1998). The LNS do-
main of b-Nrxs corresponds to the sixth LNS domain of
a-Nrxs, and its structure has been determined by X-ray
crystallography at 2.6 A˚ resolution (Rudenko et al., 1999).
The extracellular esterase domains of NLs interact with
a- and b-Nrxs in a Ca2+-dependent manner. Alternative
splicing of site A and site B in NLs strongly modulates their
affinity for a- and b-Nrxs (Comoletti et al., 2003, 2006;
Boucard et al., 2005). Likewise, extensive alternative splic-
ing occurs in neurexins as well, and insertion of an insert
into splice site 4 (SS4) of a- and b-Nrxs greatly decreases
their affinity for NLs (Ichtchenko et al., 1996). Low-resolu-
tion X-ray and neutron scattering experiments in combina-
tion with mutagenesis studies suggested that the binding
interface is near SSB of NLs and SS4 of Nrxs, although
these experiments lack molecular detail about the interac-
tion (Comoletti et al., 2007; Graf et al., 2006).
The mechanism by which NLs validate and specify syn-
apses is unknown. It is the extracellular domain of NLs thatNeuis critical for this activity rather than its cytoplasmic region
(Chubykin et al., 2007). The only known ligands for the ex-
tracellular esterase domain of NLs are a- and b-Nrxs. The
high affinity of their interaction, their similar synaptic func-
tions, and their common involvement in autism spectrum
disorders strongly suggest that NLs and Nrxs function
by binding to each other. However, the lack of a high-res-
olution structure of the NL/Nrx complex hinders the under-
standing of how these proteins act in synapse function.
We determined the three-dimensional structures of NL1
in isolation and in a complex with Nrx1b by X-ray crystal-
lography. The structure of the complex reveals a binding
interface that includes two Ca2+-binding sites and ex-
plains the role of alternatively spliced sites in the regulation
of binding. We then designed multiple mutations on the
Nrx-binding surface of NL1 to disrupt the interaction of
NL1 with Nrx1b. We confirmed the stability and wild-
type-like folding of the mutant NLs. The mutations disrupt
the NL1/Nrx1b interaction by reducing the affinity by up to
three orders of magnitude. These mutants confirm the
binding interface revealed by the NL1/Nrx1b complex
structure and could be used as molecular tools to dissect
the NL1/Nrx1b interaction in vivo.
RESULTS
Structure of Neuroligin-1
The extracellular esterase domain of NL1 (residues 46–
638, without inserts in splice sites A and B) was produced
in insect cells using the baculovirus expression system
(residue numbering includes signal peptide and splice
sites even when they are absent, see Figure S1 available
online). The purified NL1 was analyzed by multiangle laser
light scattering (data not shown), which indicated that NL1
forms a dimer of approximately 150 kDa as reported pre-
viously (Comoletti et al., 2006). Crystals of NL1 were ob-
tained in space groupP32with fourmolecules in the asym-
metric unit and diffracted to dmin = 1.8 A˚. The structure
was solved by molecular replacement with an approxi-
mate homology model of NL1 (Table 1; a simulated an-
nealing omit map is shown in Figure 1C).
NL1 has an ellipsoid shape with dimensions 68 A˚ 3
66 A˚3 48 A˚ (Figure 1A, location of the SSA and SSB splice
sites are indicated by arrows). It belongs to the class of
a/b-hydrolases together with acetylcholinesterases, bu-
tyrylcholinesterases, and cholesterol esterases, consist-
ing of a twisted b sheet surrounded by multiple helices.
N-glycosylation is observed at two of the three potential
glycosylation sites (N109 and N343), and a disulfide bond
(C512-C546) is seen that is unique to NLs (Figure 1A).
The NL1 homodimer is formed by protomers that are re-
lated by a two-fold axis, similar to what is observed in the
AChE structure. The dimer interface comprises a four-
helix bundle composed of two helices from each proto-
mer, with a buried surface area of approximately 1100 A˚2
(Figure 1B). The interaction primarily involves hydro-
phobic residues L636, L633, L629, V451, F458, W463,ron 56, 992–1003, December 20, 2007 ª2007 Elsevier Inc. 993
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Crystallographic Data
NL1 NL1/Nrx1b
Beamline ALS 8.2.1 ALS 8.2.2
Wavelength (A˚) 1.0000 1.0000
a, b, c (A˚) 173.7, 173.7, 108.0 229.8, 148.8, 123.6
Resolution (A˚) 45–1.8 50–3.5
Unique reflections 337,078 50,575
Redundancy 2.8 (2.4) 3.0 (2.3)
Completeness (%) 99.6 (99.1) 94.6 (86.9)
I/s 17.0 (1.45) 11.1 (1.65)
Rsym
a (%) 6.8% (50.9%) 9.1% (52.4%)
Refinement
NL1 NL1/Nrx1b
Rcryst/Rfree
b, c 18.5%/20.5% 24.6%/27.6%
Average bond length deviation 0.005 A˚ 0.009 A˚
Average bond angle deviation 1.26 1.4
Average thermal (B) factor 25.1 A˚2 104.8 (212.2) A˚2 d
Residues in core f-c region (%) 99.6% 98.5%
Residues in disallowed regions (%) 0% 0.2%
Values in parentheses are for the high-resolution bin.
a Rsym =
P
h
P
iIi(h)  <I(h)>/
P
h
P
iIi(h), where Ii(h) is the i
th measurement and <I(h)> is the mean of all measurements of I(h) for Miller
indices h.
b Rcryst =
P
(Fobs  kFcalc)/
P
Fobs.
c Free R value is the R value obtained for a test set of reflection (5% of total) not used during refinement.
d Values are for the three ordered NL1/Nrx1b complexes. Values in parenthesis are for the fourth weakly ordered NL1/Nrx1b
complex.and M459, flanked on one side by two hydrogen bonds
(R466-Q600, H467-K601). The structure explains the di-
mer disrupting effect of the E628A/L629A mutation stud-
ied by Dean et al. (2003) since it alters residues at the
dimerization interface; the K622A/V623A mutation pre-
sumably changes the packing of the dimerization helices
since the mutated residues face into the protein core (mu-
tations correspond to E584A/L585A and K578A/V579A
mutations in Dean et al. who used a different numbering).
Comparison of NL1 with Other
Esterase Structures
The esterase domains of NLs have 34% sequence identity
with those of AChEs. Superposition of the structures of
NL1 and AChE from torpedo californica (PDB ID 2ACE) us-
ing the program DALI (Holm and Sander, 1993) yielded
a root-mean-square (rms) deviation of 2.2 A˚ for 504 equiv-
alent a carbon atoms (Figure 2A). Superposition of NL1
with other esterase domains, such as butyrylcholinester-
ase or cholesterol esterase, produced rms deviations in
the range of 2.2–2.4 A˚. Despite the similar overall fold of
NL1 and esterases, there are major differences in the es-
terase active site region (Figure 2B). The catalytic residues994 Neuron 56, 992–1003, December 20, 2007 ª2007 Elsevierof AChEs are located in a deeply buried cavity that is sur-
face accessible through an entrance. Both sequence
identity and structural similarity between NL1 and AChE
are very low in the active site region (Figures 2B and S1).
In addition, the active site residues of AChE are solvent ac-
cessible, whereas the homologous residues in NL1 are in-
accessible to solvent due to an occluded entrance. There
are two short helices in NL1 instead of one in AChE, which
occlude the entrance. Different loop lengths cause major
structural differences in NL1 compared to AChEs (there
are eight extra residues 132–139, indicated by ‘‘1’’ in
Figure 2B, and there is a shorter loop in the region indi-
cated by ‘‘2’’ in Figure 2B).
The C-terminal subdomain containing the EF handmotif
(Tsigelny et al., 2000) is in a different position in NL1 than in
AChEs, and the helices of the EF hand motif are packing
differently (indicated by ‘‘3’’ in Figure 2B). No electron den-
sity was observed at the putative Ca2+-binding sites of the
EF handmotif for NL1 crystals that included Ca2+ (data not
shown), as well as in the Ca2+ containing crystal structure
of the NL1/Nrx1b complex (discussed below), indicating
that the EF hand motif of NL1 does not bind Ca2+, at least
not in isolation or in a complex with Nrx1b.Inc.
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Interaction between Neuroligin and NeurexinFigure 1. Structure of Neuroligin-1
(A) Ribbon diagram of a NL1 protomer. Two views are shown related by a 180 rotation around the specified axis. a-helices are colored orange and
b sheets are colored cyan. The unique disulfide bond is colored magenta.
(B) Ribbon diagram of the NL1 dimerization interface. Residues involved in hydrophobic interactions are shown in sticks and H bonds are shown by
dashed lines. The two NL1 protomers are colored orange and magenta, respectively.
(C) Simulated annealing sA-weighted Fo  Fc electron density map (magenta) with residues 395–402 omitted in all NL1 protomers, contoured at 4 s.
The omitted residues are shown as thick sticks; other residues are shown as thin lines.Structure of the NL1/Nrx1b Complex
To determine the structure of the complex, the esterase
domain of NL1 without SSA and SSB was coexpressed
with Nrx1b (residues 47–299; without an insert in SS4) in
insect cells, and the complex was formed in the presence
of 1 mM Ca2+. Crystals of the complex were obtained in
space group C2 with four NL1/Nrx1b complexes in the
asymmetric unit and diffracted to dmin = 3.5 A˚ (Table 1
anda simulated annealing omitmap is shown in Figure 3D).
The crystal structure of the NL1/Nrx1b complex com-
prises a heterotetramer in which two Nrx1b protomers
bind to equivalent sites on opposite sides of the long
axis of the NL1 dimer (Figure 3A). The NL1 dimer within
the complex is identical to the NL1 dimer observed in
the isolated NL1 structure, and the two Nrx1b molecules
that bind to the NL dimer are not interacting with each
other. The observed oligomeric state is consistent with so-
lution sedimentation velocity experiments that revealed
a 2:2 stoichiometry (Comoletti et al., 2006). Electron den-
sity is observed for twoCa2+ at the binding interface. Apart
from side-chain rotamer changes, no major conforma-
tional changes are observed when the complex structureNeuis compared with the individual structures of NL1 and
Nrx1b (rms deviation for Ca atoms is 0.4 A˚ for both NL1
and Nrx1b).
The Nrx1b-binding site on NL1 is located next to SSB
and on the opposite side of the molecule relative to the
‘‘active site’’ entrance (Figure 3B). The structure reveals
that the presence of the eight-residue SSB on NL1 would
partially occlude the interaction surface, leading to a de-
crease in binding affinity, which is in agreement with the
observations that the presence of the SSB insert abolishes
a-Nrx binding and reduces b-Nrx binding (Boucard et al.,
2005; Comoletti et al., 2006). The NL1-binding region on
Nrx1b is located at the rim of the b sheet that is opposite
to its N and C termini. The 30 residue insert of SS4 in
Nrx1b would be located next to the binding region, ex-
plaining why its presence impairs binding to NLs (Ichtch-
enko et al., 1996). The SSB of NL1 and the SS4 of Nrx1b
are located on approximately opposite sides across the
binding interface. This arrangement of the splice sites
could induce an additive effect upon introduction of both
splice sites and would thus allow complex regulation of
the strength of binding between NL1 and Nrx1b.ron 56, 992–1003, December 20, 2007 ª2007 Elsevier Inc. 995
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Interaction between Neuroligin and NeurexinFigure 2. Comparison of the NL1 and AChE Structures
(A) Superposition of NL1 (red) and AChE (cyan) (PDB code 2ACE) structures.
(B) Close-up of the ‘‘active site’’ region. Numbers on the figure correspond to the regions where a structural change occurs as explained in the
text.Mapping the residues that are mutated in some autism
cases (R451C in hNL3, G99S in hNL4, K378R in hNL4,
V403M in hNL4) on the NL1/Nrx1b structure reveals that
these residues are not at the binding interface, and thus
are unlikely to cause a direct defect in binding to Nrx1b
(Figure 3C), consistent with previous data (Chubykin et al.,
2005). All mutations except for one are located in a buried
region opposite to the Nrx1b-binding surface half way
between the ‘‘active site’’ and the dimerization interface,
likely causing folding defects of NL (Comoletti et al., 2003).
The Binding Interface of the NL1/Nrx1b Complex
The high affinity of the NL1/Nrx1b complex (Kd = 97 nM as
determined by isothermal titration calorimetry [ITC];
Figure 4A) is achieved by a combination of several interac-
tions: coordination of two Ca2+ by oxygen atoms, hydro-
gen bonds, and hydrophobic and long-range electrostatic
interactions (Figures 3B, 3E, and S2). Two long parallel
loops on the rim of the Nrx1b b sheet align with a patch
of multiple loops on NL1 to form an extensive interaction
surface with a buried area of 645 A2. One of the Ca2+ is co-
ordinated by five oxygen atoms (N238 OD1, D137 OD1,
D137 OD2, V154 O, and I236 O) from Nrx1b and three
oxygen atoms (G396 O, Q395 O, and E397 OE2) from
NL1 (Figure 3E). This Ca2+-binding site is homologous to
the Ca2+-binding site of the previously reported second
LNS domain of Nrx1a (Sheckler et al., 2006). The other
Ca2+-binding site is at the edge of the binding interface
and is loosely coordinated by three oxygen atoms (N103
O, D104 OD1, and D104 OD2) from Nrx1b and three oxy-
gen atoms (D402 OD1, D402 OD2, and T569 O) from NL1.
No Ca2+ binding was observed in this site in the Ca2+-
bound structure of the second LNS domain of Nrx1a
(Sheckler et al., 2006). Thus, Ca2+ might bind to this sec-
ond site only in the context of the NL1/Nrx1b complex.
An extensive hydrogen-bonding network is observed at
the binding interface involving NL1-R597 NE and Nrx1b-996 Neuron 56, 992–1003, December 20, 2007 ª2007 Elsevier IN103 OD1, NL1-N400 N and Nrx1b-S107 OG, NL1-K306
NZ and Nrx1b-S107 O, NL1-E397 OE2 and Nrx1b-I236
N, and NL1-G396 O and Nrx1b-N238 ND2 (Figures 3E
and S2). In addition, many residues from NL1 (H294,
E297, K306, Q395, E397, L399, N400, and F499) and
Nrx1b (N103, S107, R109, L135, R232, I236, and N238)
are involved in long-range electrostatic interactions and
hydrophobic interactions.
Sequence Conservation and Variation
of NL Surface Residues
The sequence identity between NLs is high (70%–80%).
To visualize the conserved and varying regions of NLs,
we mapped the conservation of residues between NL1
and NL2 (Figure 5A), between NL1 and NL3 (Figure 5B),
and between NL1 and NL4 (Figure 5C) on the NL1 struc-
ture and colored residues from most conserved (blue) to
least conserved (red). The binding surface for Nrx1b corre-
sponds to one of themost conserved regions (yellow ovals
in Figure 5). Specifically, most residues at the NL1/Nrx1b
interface are conserved within NLs but are not in AChEs
(Q395, E397, D402, N400, E397, H294, E297, L399)
(Figure S1). However, there are some residues at the
edges of the interaction surface that are variable among
NLs (examples are K306, F499, G500, N498, R597,
R311). These variable residues explain differences in bind-
ing affinity to Nrxs (the Kd is 97 and 830 nM for NL1 and
NL2, respectively, as determined by ITC, Figures 4A and
4B; see also Comoletti et al., 2006).
There are several other regions that are not conserved
among NLs; some of these regions might be important
for the differential activity of different NLs to specify differ-
ent synapse types. Interestingly, NL1 has a highly con-
served loop insertion that does not exist in AChEs. It forms
a loop/b sheet fold and lies close to the surface of the
structure away from the ‘‘active site’’ (residues 576–587)
(Figure 2A).nc.
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Interaction between Neuroligin and NeurexinFigure 3. Structure of the NL1/Nrx1b Complex
(A) Ribbon diagram of the NL1/Nrx1b heterotetramer.
(B) Overall view of a NL1/Nrx1b heterodimer showing carbohydrates (yellow sticks), splice sites Nrx SS4 and NL SSB (arrows) and Ca2+ ions at the
binding interface (green spheres).
(C) Ribbon diagram of the NL1/Nrx1b complex showing the location of the autism mutations (R451C in human NL3 and G99S, K378R, and V403M in
human NL4) superimposed onto the rat NL1 structure and highlighted as yellow spheres.
(D) Simulated annealing sA-weighted Fo  Fc electron density map (magenta) with residues 395–402 omitted in all NL1 protomers, contoured at 4 s.
The omitted residues are shown as thick sticks; other residues are shown as thin lines.
(E) Close-up view of the binding interface between NL1 and Nrx1b. Ca2+ are shown as green spheres. Hydrogen bonds are shown by red dashes. The
Ca2+ coordination is shown by black dashes. Residues at the binding interface are shown as sticks.Mutations at the Binding Surface Disrupt
the Interaction of NL1 with Nrx1b
To confirm the validity of the binding interface that is ob-
served in the NL1/Nrx1b complex structure, we designed
NL1 surface mutations that disrupt its interaction withNeuroNrx1b based on our crystal structures (Figure 5D). The
L399A, N400A, D402N set (NL1-LND) breaks the hydro-
gen bond between NL1 N400 and Nrx1b S107 and dis-
rupts the Ca2+ coordination mediated by NL1 D402
(shown in cyan). The NL1-LND mutant should leave then 56, 992–1003, December 20, 2007 ª2007 Elsevier Inc. 997
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Interaction between Neuroligin and NeurexinFigure 4. Different NLs and NL1 Mutants Have Different Binding Affinities for Nrx1b, and the NL1 Mutants Are Properly Folded
Titration of wild-type Nrx1b into NL1 (A), NL2 (B), and NL1-LND mutant (C) by ITC at 20C. For NL1 Kd = 97 nM, n = 1.06, DH = 12660 cal mol1,
DS = 14.5 cal mol1 K1, for NL2 Kd = 830 nM, n = 0.84, DH = 3686 cal mol1 and DS = 15.2 cal mol1 K1.
(D) CD spectra of wild-type NL1 (black), NL1-LNDEK (red), and NL1-LNDQE (green) mutants plotted as mean residue ellipticity versus wavelength.
(E) Temperature denaturation experiments of wild-type NL1 and mutant NLs (colored as in [D]). The Tm for wild-type NL1, NL1-LNDEK, and NL1-
LNDQE mutants are 56C, 58C, and 57C, respectively.other half of the binding interface intact. Starting from this
mutant, additional sites were mutated (shown in yellow).
The L399A, N400A, D402N, Q395A, E397A set (NL1-
LNDQE) also disrupts the other Ca2+ site coordinationme-
diated by NL1 E397. The L399A, N400A, D402N, E297A,
K306A set (NL1-LNDEK) additionally disturbs the two res-
idues that flank SSB.
To ensure that the mutant proteins are properly folded,
we performed circular dichroism (CD) experiments (Fig-
ure 4D). The CD spectra are characteristic of a mixture
of a-helix and b sheet as expected from the NL1 structure.
We observed few differences between wild-type and
mutant proteins. Temperature denaturation experiments
showed that the melting temperature Tm (the temperature
at which 50% of the protein is denatured) of wild-type NL1
and mutant proteins are similar. Thus, the mutations have
no effect on the folding or the stability of the protein
(Figure 4E).
It was not possible to obtain a typical ITC binding curve
for the NL1-LND mutant (Figure 4C). Increasing the injec-
tion volumes yielded higher signal but no saturation of the
signal was achieved, indicative of weak binding. We esti-
mate that the NL1-LNDmutant binds to Nrx1bwith micro-
molar affinity. We did not attempt ITC of the other mutants
that might have even weaker affinities.998 Neuron 56, 992–1003, December 20, 2007 ª2007 ElsevierIn order to determine the dissociation constants of mu-
tant neuroligins to Nrx1b, we used surface plasmon reso-
nance (SPR), a technique that canmeasure the binding af-
finities for weak interactions. The wild-type and mutant
NL1 proteins were immobilized on a surface and different
concentrations of Nrx1b (in the range of 0.18 nM–30 mM)
were injected over the NL1 surface. The binding was de-
tected by the increase in the resonance units (Figure S3)
and the dissociation constants were calculated by plotting
the steady-state binding as a function of Nrx1b concentra-
tion (Figure 6). The dissociation constant of the wild-type
NL1 was measured as 20.9 nM, in good agreement with
the results of the ITC measurements. The dissociation
constant of the NL1-LNDmutant for Nrx1bwas measured
as >10 mM, which is 500-fold less than the affinity of wild-
type NL1. The dissociation constants of the NL1-LNDQE
and NL1-LNDEK mutants, that carry LND mutation as
background, are >50 mM and >10 mM, respectively. These
results show that our mutants decrease the binding of NL1
to Nrx1b up to 2500-fold. Our properly folded NL1mutants
that are deficient in binding to Nrx1b confirm the validity of
the binding interface revealed from the NL1/Nrx1b com-
plex structure, and can be used in future experiments as
molecular tools to dissect NL-dependent neuronal events
that are Nrx independent.Inc.
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Interaction between Neuroligin and NeurexinFigure 5. Sequence Variation of NL Surface Residues and
Conservation of the NL1/Nrx1b Binding Interface
The structure of NL1 shown in surface representation on which the
conservation of residues between NL1 and NL2 (A), between NL1
and NL3 (B), and between NL1 and NL4 (C) are mapped from most
conserved (blue) to least conserved (red) (using the ConSurf server
[Landau et al., 2005]). The structure is shown in a similar orientation
as in Figure 1A. The Nrx-binding and dimerization regions are indicated
by yellow and cyan ellipses, respectively.
(D) NL1 mutations at the binding interface (see text for designa-
tion).NeurDISCUSSION
Using a combination of biophysical and biochemical ap-
proaches, we studied the structure and specificity of the
interaction between NL1 and Nrx1b. The structure of
NL1 revealed a fold similar to that of other esterase do-
mains, despite the low sequence identity (Figures 1A
and 2A). However, significant differences were observed
at the ‘‘active site’’ entrance, which is substrate-accessi-
ble in AChEs, but occluded in NL1 (Figure 2B). The NL1
structure confirms that NL1 is a constitutive dimer. Two
helices from each monomer form a four-helix bundle at
the binding interface that is primarily composed of hydro-
phobic interactions but includes a few hydrogen bonds
(Figure 1B). No Ca2+ binding was observed to the EF
hands of NL1 that were previously proposed to be the
Ca2+-binding sites.
The structure of the NL1/Nrx1b complex revealed an
arrangement of two Nrx1b protomers bound to identical
surfaces on the opposite sides of a NL1 dimer to form
a heterotetramer with a two-fold symmetry (Figure 3A).
This organization of the NL1/Nrx1b complex positions
the C-terminal stalk regions of NL1 and Nrx1b at opposite
faces of the heterotetramer and is in agreement with the
biological organization of the molecules to bridge and
cross the 20 nm-wide synaptic cleft between neurons.
The SSB of NL1 and the SS4 of Nrx1b are positioned at
the edges of the binding interface; as a result, their pres-
ence disturbs the interaction between NLs and Nrxs as re-
ported previously (Boucard et al., 2005; Comoletti et al.,
2006; Figure 3B). Expression of different splice variants
Figure 6. SPR Analysis of the Binding of Nrx1b to Wild-Type
and Mutant NL1s
Maximum binding of Nrx1b to NL1 measured at steady state during
neurexin injection over immobilized NL1s were plotted as a function
of Nrx1b concentration. The dissociation constants were calculated
by fitting the curves to a single site binding model. Each data point
wasmeasured twice, and bothmeasurements are shown on the figure.
For most data points, the twomeasurements are very similar and over-
lap with each other.on 56, 992–1003, December 20, 2007 ª2007 Elsevier Inc. 999
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ing between NLs and Nrxs to regulate their downstream
events. Mapping of the mutations of NL genes in autistic
patients on the NL1/Nrx1b complex structure reveals
that they are distant from the NL1/Nrx1b binding interface
but are located mostly within the protein core, suggesting
folding defects (Figure 3C).
The NL1/Nrx1b binding interface includes two distinct
Ca2+-binding sites (Figure 3E). The first Ca2+-binding site
is homologous to the Ca2+-binding site that was observed
in the second LNS domain of Nrx1a, which has a 400 mM
affinity for Ca2+ (Sheckler et al., 2006). The half maximal
binding of Nrx1b to NLs requires approximately 2–3 mM
free Ca2+ (Nguyen and Sudhof, 1997). The tighter binding
of Ca2+ to the NL1/Nrx1b complex can be explained by
completion of the Ca2+ coordination sphere by complex
formation. The second Ca2+-binding site is at the edge
of the interface and is more loosely coordinated. No
Ca2+ binding was observed at this site in the second
LNS domain of Nrx1a probably because of the few coor-
dination sites contributed by Nrx1a.
In addition to Ca2+ coordination, the interaction be-
tween NL1 and Nrx1b is maintained by multiple side chain
and backbone interactions from both proteins, leading to
the nanomolar affinity of the interaction (Figure 3E). Thus,
Ca2+ coordination, an extensive hydrogen-bonding net-
work, hydrophobic interactions, and long-range electro-
static interactions contribute to the high-affinity interac-
tion of NL1 with Nrx1b. Mapping the conserved and
varying residues between NLs on the NL1 structure
shows that the Nrx binding site is conserved throughout
all NLs (Figures 5A–5C) but not in AChEs (Figure S1)
and supports a critical role for the NL/Nrx interaction in
synapse function. However, variation at the edges of the
binding interface contributes to the differential NL1/
Nrx1b affinities.
To confirm that the binding interface that is revealed by
the NL1/Nrx1b complex structure is correct, we designed
NL1mutants in order to specifically disrupt the NL1/Nrx1b
interaction (Figure 5D). ITC experiments showed that mu-
tations located on one half of the binding interface (NL1-
LND) decrease the affinity of NL1 to Nrx1b (Figure 4C).
Quantitative SPR experiments confirm that NL1-LND mu-
tant has 500-fold less affinity for Nrx1b than wild-type NL1
(Figure 6). Our more severe mutants disrupted other re-
gions of the binding interface, thereby decreasing the af-
finity of NL1 for Nrx1b up to 2500-fold (Figure 6), indicating
the importance of the entire binding interface for the
strength of the NL1/Nrx1b interaction. CD experiments
showed that the mutations have no effect on the proper
folding and stability of the protein. The disruption of the
binding by these mutations confirms the binding interface
revealed by the NL1/Nrx1b complex structure.
In conclusion, we describe a structural analysis of the
interaction between NLs and Nrxs, the synaptic cell adhe-
sion proteins that are proposed to be critical for proper
synapse function. Our crystal structures of NL1 and the
NL1/Nrx1b complex provide the basis for further ad-1000 Neuron 56, 992–1003, December 20, 2007 ª2007 Elseviervances in understanding their mechanism of action in syn-
apse function whichmay lead to the treatment of diseases
that are caused by mutations in these proteins.
EXPERIMENTAL PROCEDURES
Protein Expression and Purification
The esterase domain of rat NL1 without splice sites (residues 46–638)
was cloned into the BamH1 and Xba1 sites of the pAcGP67A vector.
The LNS domain of rat Nrx1b without splice site 4 (residues 47–299)
was cloned similarly. A His6 tagwas added at theC terminus for affinity
purification. Spodoptera frugiperda (Sf9) cells (Invitrogen) were trans-
fected with pAcGP67A carrying the gene and linearized AcNPV DNA
(Sapphire Baculovirus DNA; Orbigen) using Cellfectin (Invitrogen).
Baculovirus was amplified in Sf9 cells in 10% (v/v) fetal bovine serum
containing SF900-II medium (GIBCO).
Large-scale protein expression was performed by infection of
Trichoplusiani (Hi5) cells in Insect-Xpress medium (Biowhitaker) at
a cell density of 2 3 106 cells/ml with an infection course of 72 hr.
For higher expression yields NL1 and Nrx1b were coexpressed.
When tunicamycin, a glycosylation inhibitor, was used, no protein
could be obtained. The media containing the secreted, glycosylated,
recombinant protein was concentrated and dialyzed using tangential
flow filtration system (PALL) and subsequently purified with Ni-NTA
resin (QIAGEN) at 4C. The proteins were eluted with 200 mM imidaz-
ole (pH 7.2). NL1 and Nrx1b were separated by anion exchange chro-
matography (Mono Q column) in 20 mM Tris (pH 8.0), 150 mM NaCl
(buffer A), and 20mMTris (pH 8.0), 1MNaCl (buffer B). NL1was further
purified by size-exclusion chromatography using a Superdex 200 col-
umn (Amersham Pharmacia Biotech) in buffer containing 10 mM
HEPES (pH 7.2) and 150 mM NaCl. The peak corresponding to the
NL1 dimer was then concentrated to 17 mg/ml in 30 kDa Centricon
(Millipore) and used for crystallization trials. After affinity chromatogra-
phy and anion exchange chromatography, Nrx1b was further purified
as described in the literature (Rudenko et al., 1999). The purified pro-
teins were mixed in the presence of 1 mM CaCl2 with a 1:1.3
NL1:Nrx1b ratio. The complex was purified by size-exclusion chroma-
tography using a Superdex 200 column (Amersham Pharmacia Bio-
tech) in buffer containing 10 mM HEPES (pH 7.2), 150 mM NaCl, and
1 mM CaCl2 and concentrated to 22 mg/ml.
Site directed mutagenesis for NL1mutants was performed using the
QIAGEN QuickChange Mutagenesis kit (QIAGEN).
Crystallization, Data Collection, and Processing
Initial screens for crystallization of NL1 were carried out using 96-well
format kits (Hampton Index, Salt and Crystal Screen HT, Hampton Re-
search) on a Phoenix crystallization robot (Art Robbins Instruments).
Automatic plate scanning by a CrystalPro 2 imaging system (TriTek
Corporation) identified initial hits. After optimization, crystals of NL1
were grown using hanging drop vapor diffusion at 20C in 24-well
format. One microliter of 17 mg/ml protein in 10 mM HEPES (pH
7.2), 150 mMNaCl was mixed with equal volume of mother liquor con-
sisting of 1.2 M tri-sodium citrate, 0.1 M Tris (pH 8.7), and equilibrated
against 1 ml mother liquor. Crystals grew to full size (about 0.2 mm 3
0.2 mm 3 0.6 mm) within 3 days. Crystals were cryoprotected by
transferring the crystals into mother liquor with 5%, 15%, and 22.5%
EG gradually. Many crystals suffered from cracking and thus produced
extra lattices in the diffraction images. The best crystals diffracted to
dmin = 1.8 A˚. Crystals of NL1 formed in space group P32 with four mol-
ecules per asymmetric unit and 61% solvent content.
Crystallization trials for the NL1/Nrx1b complex were obtained with
a 96-well format kit (Protein Complex, Nextal) at 20C. 22 mg/ml pro-
tein in 10 mM HEPES, 150 mM NaCl, 1 mM CaCl2 (pH 7.2) was mixed
with equal volume of mother liquor consisting of 8% PEG6000, 0.1 M
MgCl2, 0.1 M MES (pH 6.0). Crystals grew to full size (about 0.3 mm3
0.3 mm 3 0.4 mm) within five days and were cryoprotected with 25%Inc.
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complex formed in space group C2 with four NL1/Nrx1b complexes
per asymmetric unit and 64% solvent content. Indexing, integration,
and scaling of the diffraction data was performed with HKL2000
(Otwinowski andMinor, 1997). A summary of the data collection statis-
tics is given in Table 1.
Structure Determination and Refinement of NL1
The NL1 structure was solved bymolecular replacement with PHASER
(McCoy et al., 2005) using a homology model of the NL1 structure
based on the AChE crystal structure (PDB ID 1J06) (Bourne et al.,
2003). The NL1 structure was first refined with CNS 1.2 (Brunger
et al., 1998; Brunger, 2007) followed by automatic model building in
ARP/WARP (Perrakis et al., 2001) and RESOLVE (Terwilliger, 2003).
Noncrystallographic symmetry (NCS) restraints were used during ini-
tial refinement cycles but were removed at later stages. The presence
of a NCS two-fold symmetry axis that coincided with one of the cell
axes would cause the test set to be correlated to the working set. To
ensure independence of the test set from the working set, the diffrac-
tion data was first scaled in the higher symmetry group P6 while gen-
erating the test set, then the test set was expanded to lower symmetry
in P32 and transferred to the diffraction data processed in P32. The
refinement consisted of alternating rounds of simulated annealing, po-
sitional minimization, individual restrained thermal factor refinement,
and model building. Positional minimization was performed using
the MLF maximum likelihood target function. Water molecules,
N-linked carbohydrates, and alternative conformations were added
in CNS 1.2 and COOT (Emsley and Cowtan, 2004), and refinement
was completed with CNS 1.2. The bulk solvent model refined to
ksol = 0.4 e/A˚
3 and Bsol = 55 A˚
2. The final model contains two N-linked
NAG carbohydrate moieties attached to each of the NL1 molecules,
and two bound Ni2+.
Structure Determination and Refinement
of the NL1/Nrx1b Complex
The NL1/Nrx1b crystal structure was solved bymolecular replacement
usingPHASER (McCoy et al., 2005)with thehigh-resolution structure of
NL1 and the structure of Nrx1b (PDB code 1C4R) (Rudenko et al., 1999)
as search models. An initial solution emerged with three NL1-Nrx1b
complexes, two of which form the dimer that was also found for the
isolated NL1 structure. Inspection of a sA weighted 2Fo  Fc electron
density map revealed the presence of a weakly ordered fourth NL1/
Nrx1b complex that also had a two-fold relationship with the remaining
well-ordered NL1/Nrx1b complex. This weakly ordered NL1/Nrx1b
complex was modeled by applying the two-fold relationship to the co-
ordinates of its interacting ordered NL1/Nrx1b complex. All refinement
calculationswere performedwithCNS1.2. Positionalminimizationwas
performed using the MLF maximum likelihood target function. Tight
NCS restraints were applied to all atomic positions for the four NL1/
Nrx1b complexes, resulting in rmsds of less than 0.03 A˚ among the
NCS related NL1/Nrx1b complexes. Individual restrained B-factor
minimization was performed for the three well-ordered NL1/Nrx1b
complexwith tightNCS restraints. The fourth complexwas treatedsep-
arately by using grouped B-factor minimization since it exhibits some
amount of disorder and weak electron density. The bulk solvent model
refined to ksol = 0.3 e/A˚
3 andBsol = 67 A˚
2. Inspection of the electron den-
sity maps revealed weak electron density for the following loops: NL1
577–591, NL1 637–642, NL1 445–450, Nrx1b 289–291. Minor adjust-
ments of the model were performed using COOT, followed by another
round of refinement. The final model contains three N-linked NAG
carbohydrate moieties attached to each of the NL1 molecules, two
attached to the well-ordered Nrx1b molecules, and two Ca2+ bound
to each of the interfaces of the well-ordered NL1/Nrx1b complexes.
Isothermal Titration Calorimetry
Wild-type NL1, NL2, NL1-LND mutant, and Nrx1b proteins were dia-
lyzed against a buffer solution containing 10 mM HEPES (pH 7.2),Neuron150mMNaCl, and 1mMCaCl2 three times for 1 hr, 3 hr, and overnight.
The final buffer was saved to be used as washing buffer for the ITC in-
strument. The ITC experiments were carried out with a VP-ITC Micro-
Cal calorimeter. Samples were degassed for 10 min before the exper-
iment. The wild-type or mutant NL1 protein solutions (20–30 mM range)
were placed in the MicroCal sample cell. The Nrx1b protein solution
(200 mM)was placed in a syringe andwater was placed in the reference
cell. The Nrx1b solution in the syringe was added to the cell in a series
of multiple injections of varying injection volumes (2 ml into wild-type
NL1, 5 ml into wild-type NL2, and 10 ml into NL1-LND mutant to opti-
mize the signal level) at 20C. Titration of Nrx1b into a solution of NL
generated an exothermic reaction, releasing heat upon binding of
Nrx1b to NL. The raw ITC data was processed and fitted using amodel
for single molecule site. The raw ITC data were deconvoluted using the
ORIGIN software provided by MicroCal.
CD Spectroscopy
CD measurements were conducted on a Aviv Circular Dichroism
Spectrometer Model 202-01 equipped with a temperature controller.
Ten micromolar samples of wild-type and mutant NL1 proteins in
20 mM Tris (pH 8.0), 150 mM NaCl buffer solution were scanned in
the 195 nm to 270 nm range, with 1 nm wavelength steps, in a 1 mm
path length cell at 4C. Temperature denaturation experiments were
performed at 220 nm wavelength by increasing the temperature from
25C to 80C with 2C temperature increments, two minutes temper-
ature equilibration time and 3 s averaging time.
Surface Plasmon Resonance
Binding of Nrx1b to WT and mutant NL1 was analyzed at 25C using
10 mM HEPES buffer (pH 7.4) containing 1 mM CaCl2, 150 mM NaCl,
0.005%(v/v) surfactant P20 and 1%BSA, on a BIAcore 3000. Control
protein, WT, and mutant neuroligin proteins were covalently attached
to carboxymethylated dextran of a research grade CM3 chip (BIAcore,
Uppsala, Sweden) by NHS/EDC amine coupling and a resonance unit
of 600–700 was achieved for all samples. Nrx1b was injected over the
NL1 surfaces as a set of concentrations differing by 3-fold in the range
of 0.18 nM–30 mM and each data point was measured twice. A flow
rate of 50 ml/min was used to minimize sample diffusion and mass
transport limitations. Reference data obtained using a flow-cell with
immobilized control protein (inactive BotA) were subtracted from the
sample flow channels to obtain a specific Nrx1b binding. NL1 surfaces
were regenerated by the injection of a regeneration solution (10 mM
HEPES [pH 7.4], 1 M NaCl, 3 mM EDTA, 0.005% P20 and 1%BSA).
For analysis of steady-state binding affinities, the magnitude of the re-
sponse at the end of each injection were measured and fitted using
a single site stoichiometry model.
Figure Preparation
All figures were prepared using PyMol (DeLano, 2002).
Supplemental Data
The Supplemental Data for this article can be found online at http://
www.neuron.org/cgi/content/full/56/6/992/DC1/.
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